Cutting the high cost and heartache of in-vitro fertilization isn’t as easy as Silicon Valley thought. Progyny, a startup that bills itself as “the Uber of fertility” as it touts new tactics and technologies to democratize the $10 billion-a-year IVF industry, has been forced to flip its strategy over the past six months in a bid to keep itself alive — and on the right side of health regulators, according to an investigation by The Post.
It Turns Out It’s Really Tough to ‘Disrupt’ Childbirth
